Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)

被引：0

作者：

Prajapati, Vimal H. ^{[1
,2
,3
,4
,5
,6
,7
]}

Rosmarin, David ^{[8
]}

Shumack, Stephen ^{[9
,10
,11
]}

Calimlim, Brian M. ^{[12
]}

Takemoto, Shunya ^{[10
]}

Hu, Xiaofei ^{[12
]}

Ladizinski, Barry ^{[12
]}

Warren, Richard B. ^{[13
]}

机构：

[1] Univ Calgary, Div Dermatol, Calgary, AB, Canada

[2] Univ Calgary, Dept Pediat, Sect Community Pediat, Calgary, AB, Canada

[3] Univ Calgary, Dept Pediat, Sect Pediat Rheumatol, Calgary, AB, Canada

[4] Univ Calgary, Dept Med, Calgary, AB, Canada

[5] Skin Hlth & Wellness Ctr, Calgary, AB, Canada

[6] Dermatol Res Inst, Calgary, AB, Canada

[7] Prob Med Res, Calgary, AB, Canada

[8] Tufts Med Ctr, Dept Dermatol, Boston, MA 02111 USA

[9] Univ Sydney, Sydney Med Sch Northern, Sydney, NSW, Australia

[10] Skin Hosp, Darlinghurst, NSW, Australia

[11] Royal North Shore Hosp Sydney, Sydney, NSW, Australia

[12] AbbVie Inc, N Chicago, IL USA

[13] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

174

引用

页码：E81 / E81

页数：1

共 50 条

[31] Characterization of hematologic and transaminase laboratory findings associated with upadacitinib in moderate-to-severe atopic dermatitis: Results of two phase 3 trials (measure up 1 and 2)
Silverberg, Jonathan I.
Gooderham, Melinda J.
de Bruin-Weller, Marjolein S.
Papp, Kim A.
Aoki, Valeria
Paller, Amy S.
Ofori, Sarah
Tenorio, Allan R.
Liu, Yingyi
Liu, Jianzhong
Chovatiya, Raj
CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1010 - 1010
[32] Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2)
Silverberg, J. I.
Thyssen, J. P.
Rosmarin, D.
Pink, A. E.
Calimlim, B. M.
Teixeira, H. D.
Hu, X.
Yang, Y.
Thaci, D.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E124 - E125
[33] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
Guttman-Yassky, Emma
Teixeira, Henrique D.
Simpson, Eric L.
Papp, Kim A.
Pangan, Aileen L.
Blauvelt, Andrew
Thaci, Diamant
Chu, Chia-Yu
Hong, H. Chih-Ho
Katoh, Norito
Paller, Amy S.
Calimlim, Brian
Gu, Yihua
Hu, Xiaofei
Liu, Meng
Yang, Yang
Liu, John
Tenorio, Allan R.
Chu, Alvina D.
Irvine, Alan D.
LANCET, 2021, 397 (10290): : 2151 - 2168
[34] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
Simpson, Eric L.
de Bruin-Weller, Marjolein S.
Prajapati, Vimal H.
Calimlim, Brian M.
Teixeira, Henrique D.
Zeng, Jiewei
Liu, Meng
Silverberg, Jonathan I.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB60 - AB60
[35] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: results from the pivotal phase III, randomized, double-blind, placebo-controlled AD Up study
Reich, K.
Teixeira, H. D.
De Bruin-Weller, M.
Bieber, T.
Soong, W.
Kabashima, K.
Werfel, T.
Zeng, J.
Huang, X.
Hu, X.
Ladizinski, B.
Chu, A. D.
Silverberg, J. I.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E59 - E60
[36] Maintenance of efficacy and safety with lebrikizumab up to one year of treatment in patients with moderate-to-severe atopic dermatitis with or without topical corticosteroids
Guttman-Yassky, E.
Weidinger, S.
Silverberg, J.
Gooderham, M.
Thyssen, J.
Irvine, A.
Elmaraghy, H.
Natalie, C.
Hu, C.
Pierce, E.
Gil, E. G.
Simpson, E.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S348 - S348
[37] Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
Silverberg, Jonathan I.
Thyssen, Jacob P.
Rosmarin, David
Pink, Andrew E.
Calimlim, Brian M.
Teixeira, Henrique D.
Hu, Xiaofei
Yang, Yang
Thaci, Diamant
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB7 - AB7
[38] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
Reich, Kristian
Teixeira, Henrique D.
de Bruin-Weller, Marjolein
Bieber, Thomas
Soong, Weily
Kabashima, Kenji
Werfel, Thomas
Zeng, Jiewei
Huang, Xiaohong
Hu, Xiaofei
Hendrickson, Barbara A.
Ladizinski, Barry
Chu, Alvina D.
Silverberg, Jonathan I.
LANCET, 2021, 397 (10290): : 2169 - 2181
[39] Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis
Feldman, Steven R.
Thaci, Diamant
Gooderham, Melinda
Augustin, Matthias
de la Cruz, Claudia
Mallbris, Lotus
Buonanno, Marjorie
Tatulych, Svitlana
Kaur, Mandeep
Lan, Shuping
Valdez, Hernan
Mamolo, Carla
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (06) : 1162 - +
[40] Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: results up to Week 48 of the STARDUST trial
Danese, S.
Vermeire, S.
D'Haens, G.
Panes, J.
Dignass, A.
Magro, F.
Nazar, M.
Le Bars, M.
Lahaye, M.
Ni, L.
Bravata, I.
Gaya, D. R.
Peyrin-Biroulet, L.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S330 - S331

← 1 2 3 4 5 →